Summit Therapeutics Inc.
ivonescimab
NSCLC
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for ivonescimab in NSCLC are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“HARMONi: BLA Decision in 2L+ EGFRm NSCLC expected”